{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Ftoga-podcast.simplecast.com%2Fepisodes%2Ftargeting-vegf-in-thoracic-oncology-hUxCEcE6","width":444,"version":"1.0","type":"rich","title":"Targeting VEGF in Thoracic Oncology","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/37b381d6-a6e7-4025-a6ac-23a0ce7134b8/decb75ce-8f96-4b84-b1db-e632df66abe6/cropped_1790036851851.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/9761dc01-0e68-4bb9-92d0-5b5dbf19ef63\" height=\"200\" width=\"100%\" title=\"Targeting VEGF in Thoracic Oncology\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode of Conversations in Lung Cancer Research, host A/Prof Prunella Blinman (Medical Oncologist from Concord Hospital, Sydney) is joined by world-leading thoracic medical oncologists Prof Nick Pavlakis (Royal North Shore Hospital, Sydney) and Prof Sanjay Popat (The Royal Marsden Hospital, London) to discuss the evolving role of Vascular Endothelial Growth Factor (VEGF) in thoracic malignancies. Together, they explore the biology of VEGF and its impact on the tumour microenvironment, trace the history and safety lessons of anti-VEGF therapies from early trials like ECOG 4599 to IMpower150, and highlight emerging breakthroughs and examine emerging approaches including PD-1/VEGF bispecific antibodies, HARMONi-2 and novel combinations with ADCs."}